paperKB
coga / coga-kb
Processing
Help
Sign in

Chunk #13 — RESULTS — Participant characteristics

Source
Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer's disease.
Embedded
yes

Text

Of the 282 participants who met the inclusion criteria, 67% had very mild AD dementia (CDR 0.5) and 33% had mild AD dementia (CDR 1) (Table 1). The sample overall was 88% non‐Hispanic White and 10% Black or African American. Slightly more participants were men (56%). Most participants were well educated, with an average of 15.1 years of education. The 282 participants were followed for an average of 2.9 years (participants who progress to CDR 2 or greater no longer are assessed with the UDS).